Neutron-Activatable Holmium-Containing Mesoporous Silica Nanoparticles as a Potential Radionuclide Therapeutic Agent for Ovarian Cancer

• DOI: 10.2967/jnumed.112.106609
• Publication Date: 2012-10-26T03:41:56Z
• Authors: Anthony J. Di Pasqua; Hong Yuan; Younjee Chung; Jin-Ki Kim; James E. Huckle; Chenxi Li; Matthew Sadgrove; Thanh Huyen Tran; Michael Jay; Xiuling Lu
• Keywords: Biodistribution; Radionuclide therapy

Mesoporous silica nanoparticles (MSNs) were explored as a carrier material for the stable isotope ¹⁶⁵Ho and, after neutron capture, its subsequent therapeutic radionuclide, ¹⁶⁶Ho (half-life, 26.8 h), use in radionuclide therapy of ovarian cancer metastasis. <b>Methods:</b>¹⁶⁵Ho-MSNs prepared using ¹⁶⁵Ho-acetylacetonate and MCM-41 particles, stability was determined irradiation nuclear reactor (reactor power, 1 MW; thermal flux approximately 5.5 × 10¹² neutrons/cm²·s). SPECT/CT tissue biodistribution studies performed intraperitoneal administration ¹⁶⁶Ho-MSNs to SKOV-3 tumor–bearing mice. Radiotherapeutic efficacy studied by PET/CT with ¹⁸F-FDG determine tumor volume monitoring survival. <b>Results:</b> The holmium-MSNs able withstand long times did not release significant dilution. images distribution results revealed that accumulated predominantly tumors (32.8% ± 8.1% injected dose/g 24 h; 81% 7.5% wk) administration. showed reduced uptake tumors, which correlated marked increase survival treatment 4 MBq ¹⁶⁶Ho-MSNs. <b>Conclusion:</b> retention holmium during vivo well their extending tumor-bearing mice underscores potential radiotherapeutic agent